Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antelope: Biosimilar Natalizumab PB006 vs Tysabri in Relapsing-Remitting Multiple Sclerosis
2018-004751-20Phase 3Completed
- Sponsor
- Polpharma Biologics
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of PB006 in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Polpharma Biologics. Primary endpoint: Cumulative number of new active lesions. Started Apr 2019; status: completed.
02
Drugs
PB006
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2018-004751-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004751-20.